Astonea Labs Ltd

Astonea Labs Ltd announced that its members, at the 9th Annual General Meeting held on August 21, 2026, approved a special resolution to alter the Object Clause of the Memorandum of Association (MOA). This alteration aims to broaden the company's business scope to include manufacturing, processing, marketing, distribution, and sale of pharmaceutical, nutraceutical, healthcare, and ayurvedic products. The company will also engage in various commercial channels like retail, wholesale, institutional sales, franchising, and e-commerce. This strategic move aligns the company's objectives with its existing and proposed business activities in the health and wellness sector.

Astonea Labs Ltd announced the re-appointment of Ms. Pooja Singh as a Director of the Company at its 9th Annual General Meeting held on August 21, 2026. Ms. Singh, who was liable to retire by rotation, was eligible and offered herself for re-appointment. She holds a B.Pharm degree and has over eight years of experience in the pharmaceutical industry, specializing in Quality Assurance and Drug Regulatory Affairs. She joined Astonea Labs in 2021 and currently leads the Drug Regulatory Affairs department. Ms. Singh is not related to any other director or key managerial personnel and has no directorships in other listed entities, though she is a member of the CSR Committee at Astonea Labs.

Astonea Labs Ltd has submitted its Annual Report for the Financial Year 2025-26, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, approved by the Board on July 24, 2026, includes the Notice for the 9th Annual General Meeting, Board's Report, Audited Financial Statements, and Statutory Auditors' Report. The company focuses on holistic wellness and anti-aging through pharmaceuticals and nutraceuticals, emphasizing innovation, research, and development. The report details business segments, vision, mission, values, product portfolio, manufacturing capabilities, leadership, governance, financial performance, strategic growth plans, risk management, and CSR initiatives. It also contains detailed financial statements and shareholder information.

Astonea Labs Ltd has announced its 9th Annual General Meeting (AGM) for the Financial Year 2025-26. The meeting is scheduled to be held on Friday, August 21, 2026, at 11:30 AM at Mercure Hotel, Chandigarh. The notice, along with the explanatory statement, was approved by the Board of Directors on July 24, 2026. The company will provide a remote e-voting facility for members from August 18 to August 20, 2026. The Register of Members and Share Transfer Books will be closed from August 15 to August 21, 2026, for the purpose of the AGM.

Astonea Labs Ltd announced a revision to its Board Resolution dated May 30, 2026, concerning the appointment of its Tax Auditor. The amendment, approved by the Board on July 24, 2026, updates statutory references from the Income-tax Act, 1961, to the Income-tax Act, 2025, including Section 63. M/s. Avnish Sharma & Associates, Chartered Accountants, are re-appointed as Tax Auditor for Tax Year 2026-27. This change is consequential and does not affect the auditor's appointment, remuneration, or terms. The firm has experience in taxation, audit, and advisory services.

Astonea Labs Limited announced that its Board of Directors, in a meeting held on July 24, 2026, approved the Audited Consolidated Financial Results for the half-year and financial year ended March 31, 2026. The approval was delayed due to the pending audit report of its associate company, Damaira Pharmaceuticals Private Limited. The company also took on record the Statutory Auditors' Report, which contained an unmodified opinion. The Board further approved the Board's Report and the Annual Report for the financial year 2025-26. The trading window for securities will reopen 48 hours after the declaration of these results.

Astonea Labs Limited announced the outcome of its Board Meeting held on July 24, 2026. The Board approved the Audited Consolidated Financial Results for the half-year and financial year ended March 31, 2026. The approval was delayed due to the pending audit report of its associate company, Damaira Pharmaceuticals Private Limited. The Board also approved the Board's Report and the Annual Report for the financial year 2025-26. The trading window for securities will reopen 48 hours after the declaration of these results.

Astonea Labs Ltd has announced a Board of Directors meeting scheduled for July 24, 2026. The primary agenda items include the consideration and approval of the Audited Consolidated Financial Results for the Financial Year ended March 31, 2026. The meeting will also address the Notice for the 9th Annual General Meeting, the Annual Report for FY 2025-26, proposed alterations to the Memorandum of Association, and the incorporation of a new subsidiary. The trading window for company shares remains closed until 48 hours after the declaration of the consolidated financial results.

Astonea Labs Ltd has executed and registered a Sale Deed on July 17, 2026, for the sale of two commercial units (FF-508 and FF-509) in JMD Megapolis, Gurugram. Each unit, measuring 1,361 sq. ft., was sold for approximately ₹1.4971 crore, totaling ₹2.9942 crore. The transaction aims to monetize immovable assets and optimize the company's portfolio. The purchasers are Mr. Suresh Kumar Satija and Mrs. Santosh Satija. The company expects this to strengthen its financial position without adversely impacting business operations.

Astonea Labs Ltd has successfully completed a regulatory inspection of its manufacturing facility located in Panchkula, Haryana, conducted by the Supreme Board of Drugs and Medical Appliances (SBDMA), Ministry of Health and Population, Republic of Yemen. The company received a certificate today confirming the successful completion of this inspection. This signifies compliance with international regulatory standards for its manufacturing operations.